Treatment of Heavy Menstrual Bleeding

First-Line Medical Treatment

• NSAIDs are the recommended first-line pharmacologic treatment for heavy menstrual bleeding, prescribed for 5-7 days during menstruation only, according to the American College of Obstetricians and Gynecologists 1, 2, 3
• Multiple NSAIDs have demonstrated statistically significant reductions in menstrual blood loss, including mefenamic acid, naproxen, indomethacin, flufenamic acid, and diclofenac sodium, as recommended by the Centers for Disease Control and Prevention 4, 1, 2
• Treatment duration should be limited to 5-7 days during active bleeding days only, as suggested by the American College of Obstetricians and Gynecologists 1, 2, 3
• Avoid aspirin, as it does not reduce bleeding and may actually increase blood loss in women with lower baseline menstrual blood loss, according to the American College of Obstetricians and Gynecologists 2

Critical Contraindications

• NSAIDs must be avoided in women with cardiovascular disease due to increased risk of myocardial infarction and thrombosis, as warned by the American Heart Association 2, 3
• Screen for cardiovascular risk factors before initiating NSAID therapy, as recommended by the American College of Cardiology 3

Second-Line Medical Treatment

• The Levonorgestrel-Releasing Intrauterine Device (LNG-IUD) is the most effective medical treatment for heavy menstrual bleeding, reducing menstrual blood loss by 71-95%, according to the American College of Obstetricians and Gynecologists 1, 2, 3
• Over time, many women experience only light menstrual bleeding or amenorrhea with the LNG-IUD, as reported by the American College of Obstetricians and Gynecologists 2
• The LNG-IUD can be used through menopause in perimenopausal women, as suggested by the North American Menopause Society 3
• Tranexamic acid is a non-hormonal alternative that reduces menstrual blood loss by approximately 80 mL per cycle, according to the American College of Obstetricians and Gynecologists 1
• Tranexamic acid is absolutely contraindicated in women with active thromboembolic disease, history of thrombosis, or cardiovascular disease, as warned by the American Heart Association 1, 2, 3

Essential Initial Assessment

• Rule out pregnancy in all reproductive-age women with abnormal bleeding, as recommended by the American College of Obstetricians and Gynecologists 1, 3
• Assess for structural causes including fibroids, polyps, adenomyosis, endometrial pathology, or malignancy, as suggested by the American College of Obstetricians and Gynecologists 3
• Evaluate for coagulopathies if clinically indicated, as up to 20% of women with heavy menstrual bleeding may have an underlying inherited bleeding disorder, according to the National Hemophilia Foundation 1

Important Counseling Points

• Enhanced counseling about expected bleeding patterns and reassurance that bleeding irregularities with certain treatments can improve treatment adherence, as recommended by the Centers for Disease Control and Prevention 4, 1

Medical Management of Heavy Menstrual Bleeding in Specific Scenarios

Treatment Options for Uterine Fibroids with Heavy Bleeding

• The American College of Radiology recommends first-line medical management with NSAIDs and estrogen-progestin oral contraceptive pills to reduce bleeding symptoms in patients with uterine fibroids and heavy bleeding 5
• Tranexamic acid is a nonhormonal alternative agent that may reduce bleeding symptoms in patients with fibroids, according to the American College of Radiology 5
• Second-line options for uterine fibroids with heavy bleeding include parenteral GnRH agonists and oral GnRH antagonists, which reduce both bleeding symptoms and tumor volume, as recommended by the American College of Radiology 5
• Combination treatment with low doses of estrogen and progestin is FDA-approved for fibroid-related heavy menstrual bleeding and mitigates hypoestrogenic effects, as noted by the American College of Radiology 5

Management of Heavy Bleeding While Taking Progesterone

Immediate Assessment and Treatment

• The American Academy of Family Physicians recommends ruling out pregnancy immediately with a beta-hCG test in all reproductive-age women with abnormal bleeding 6
• The American Academy of Family Physicians suggests considering alternative treatments, such as combined hormonal contraceptives, which contain both estrogen and progestin at higher doses than hormone replacement therapy, but may have a higher thrombotic risk than standard HRT 7
• NSAIDs taken for 5-7 days during menstruation can reduce heavy bleeding, according to the MMWR Recommendations and Reports 8

Best Treatment Options

• The American Academy of Family Physicians recommends considering switching to a levonorgestrel-releasing intrauterine device (LNG-IUD) as a first-line treatment, as it reduces menstrual blood loss by 71-95% and is more effective than oral progesterone 6
• Combined hormonal contraceptives can be considered as an alternative treatment, as they contain both estrogen and progestin at higher doses than hormone replacement therapy, but may have a higher thrombotic risk than standard HRT 7

Important Considerations

• The American Academy of Family Physicians warns against assuming the bleeding will resolve on its own without addressing the underlying issue 6
• The Blood Reviews journal notes that combined hormonal contraceptives may have a higher thrombotic risk than standard HRT 7

Tranexamic Acid for Heavy Menstrual Bleeding

Efficacy in Reducing Menstrual Blood Loss

• Tranexamic acid, a non‑hormonal antifibrinolytic, decreases menstrual blood loss by roughly 34 %–60 % when taken for 4–5 days beginning on the first day of menses in reproductive‑age women with heavy menstrual bleeding. 9

Role in Fibroid‑Related Heavy Bleeding

• For women whose heavy menstrual bleeding is caused by uterine fibroids, the standard first‑line pharmacologic approach remains NSAIDs plus estrogen‑progestin oral contraceptives; tranexamic acid serves as an effective non‑hormonal alternative when hormonal therapy is unsuitable. 9

Management of Heavy and Intermenstrual Bleeding in Copper IUD Users

Comparative Effectiveness of NSAIDs vs Tranexamic Acid

• In women using a copper intrauterine device (IUD) with heavy menstrual bleeding, mefenamic acid reduces menstrual blood loss significantly more than tranexamic acid (mean difference ≈ ‑64 mL; 95 % CI ‑106 to ‑23) based on one randomized trial of 94 participants. CDC classifies this evidence as low‑to‑moderate quality. 10
• No clinically important difference was observed in the duration of bleeding between mefenamic acid and tranexamic acid (mean difference ≈ 0.1 day; 95 % CI ‑0.3 to 0.4) across two trials involving 152 participants. CDC classifies this evidence as low‑to‑moderate quality. 11

First‑Line Pharmacologic Therapy

• The CDC recommends initiating treatment with mefenamic acid 500 mg three times daily for 5–7 days of active bleeding as the first‑line option. 12
• NSAIDs—including mefenamic acid, naproxen, indomethacin, and diclofenac—have demonstrated statistically significant reductions in menstrual blood loss in copper IUD users, supporting their use as first‑line agents. CDC rates the supporting evidence as low‑to‑moderate quality. 10
• Mefenamic acid has been evaluated in three randomized trials specifically in copper IUD users, all showing favorable outcomes on bleeding reduction. CDC rates the evidence as low‑to‑moderate quality. 12

Second‑Line Pharmacologic Therapy

• When NSAIDs are ineffective or contraindicated, tranexamic acid may be used; a study of 19 copper IUD users showed a significant reduction in menstrual blood loss compared with placebo. CDC classifies this evidence as low‑to‑moderate quality. 11

Safety and Contraindications

• Tranexamic acid is absolutely contraindicated in women with active thromboembolic disease (e.g., recent deep‑vein thrombosis, pulmonary embolism). CDC rates the safety data as moderate quality. 12

Pre‑treatment Evaluation

• Prior to initiating pharmacologic therapy, clinicians should exclude underlying causes of abnormal bleeding, including displacement of the IUD. CDC recommends this evaluation as a standard precaution. 10

Evidence Gaps and Limitations

• Evidence specific to copper IUDs with a silver core is limited because most studies do not differentiate between IUD sub‑types. CDC notes the evidence base as low quality. 11
• Data on optimal dosing regimens, treatment duration, and comparative effectiveness of different NSAIDs are limited, reflecting low‑to‑moderate quality evidence. CDC highlights the need for further research. 10

Intermenstrual (Spotting) Bleeding

• Intermenstrual spotting is common during the first 3–6 months of copper IUD use, is generally benign, and tends to diminish with continued use. CDC considers this observational finding to be of low quality. 12
• Evidence for specific pharmacologic treatment of intermenstrual spotting is scarce; a small study found no improvement with three different NSAIDs. CDC rates this evidence as very low quality. 12